NICE will be undertaking a guidance update for [TA742] Selpercatinib for treating advanced thyroid cancer with RET alterations which recommended the use of Selpercatinib in the Cancer Drugs Fund while further data were collected. The aim of the update is to decide whether or not the drug can be recommended for routine use after data collection is complete.
Please see draft timelines we have planned for your information. Following conversations with the company the appraisal is expected to start in approximately early December 2023 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an Invitation to Participate in the appraisal during early February 2024 when we will write to you about how you can get involved.